Back
PROCEPT BioRobotics
IPOPRCT.NASDAQPast

PROCEPT BioRobotics

Surgical & Medical Instruments & Apparatus

Company website ↗
Foundation year: 2007
IPO date
14/09/2021

About

Total Funding 

$443.3M


PROCEPT is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.


Number of employees

200 - 500


Headquarters

Redwood City, CA, US

Underwriters

Fidelity, Viking Global Investors, Novo Holdings